From MarketBeat:

EFG Asset Management North America Corp. bought 163,024 shares of Roivant Sciences Ltd. stock, valued at approximately $1,908,000, in the third quarter. Several other hedge funds have also increased their stakes in Roivant Sciences, with an estimated 64.76% of the stock currently owned by hedge funds and other institutional investors.

Wall Street analysts have given Roivant Sciences a “Moderate Buy” rating with an average target price of $16.56. The company has received several “buy” ratings from various analysts, with price targets ranging from $14.00 to $23.00.

Major shareholder Vivek Ramaswamy sold 3,000,000 shares of Roivant Sciences stock for a total value of $33,150,000. This sale was disclosed in a filing with the Securities & Exchange Commission, and corporate insiders now own 4.60% of the company’s stock.

Shares of ROIV stock opened at $10.35 on Friday, with a 12-month low of $6.59 and a high of $13.24. The company reported earnings of ($0.33) per share for the quarter, with $37.10 million in revenue. On average, analysts expect Roivant Sciences to post -1.77 earnings per share for the current fiscal year.

Roivant Sciences is a commercial-stage biopharmaceutical company that develops and commercializes medicines for inflammation and immunology areas. The company utilizes a unique model to develop and commercialize its medicines, focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.



Read more: 163,024 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by EFG Asset Management North America Corp.